Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This is accurate information to refute the malicious FUD that is being distributed.
Modrica said..
"ISCO secured almost 16 millions $ since July , that will be enough till 2016 at least
people read from conference calls :
<< read the fact from cc :
<< in July we raised approximately $3 million, most of which came from a group of new investors new to ISCO. The capital will be used to fund our R&D programs, primarily our Parkinson's disease program where we intend to start a clinical trial in 2014.
As part of the offering, we also issued B Warrants which expired in October of this year, and we now have, through the execution of these B Warrants, raised a total of about $5.45 million from this transaction which along with our continued ability to manage our burn rate successfully downwards, now funds the Company well into 2014. >>
so funds raise in July will get ISCO well into 2014
In December ISCO secured another 10.25 millions $ from With Lincoln Park Capital Fund, LLC
10.25 millios will be with minimal dilution because there are no warrants or convertibles
The Company controls the timing and amount of any future investment and LPC is obligated to make such purchases.
read :
<< There are no upper limits to the price LPC may pay to purchase ISCO common stock .... and .... LPC has agreed not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of the Company's shares of common stock >>
ih.advfn.com/p.php?pid=nmona&article=60351106
these are all facts and not forward looking statements
on top 5 millions yearly revenues and increasing, revenues has increased for last 4 quarters and trend is expected to continue
ISCO in 2013 had more than 3 millions in gross profits
imo
gl
mod"
Good info. It's hard to go broke if you're debt free.
Modrica said...
"ISCO is almost debt free entity (check financials) with lots of cash/funds into 2016
these are facts
next leg up should be coming real soon
once trials are underway we be looking at couple of bucks
in my opinion
gl
mod"
Other countries like China are a problem for every company with IP in any industry. If they can, they will steal your technology and good luck getting protection from the Chinese government.
In this case, if another company tries to enter the US market with a drug based on Rose Bengal, that company would have to take it through the FDA's multi-year process. And while that was happening, I expect that PVCT would be suing them in Federal Court for patent infringement. I would expect this to also be the case in the EU, Australia, Canada, and every other western country.
If in fact PVCT has decent patents, I think it very unlikely that a legitimate pharmaceutical company would pursue such a risky strategy.
Paulness said...
"I was wondering how they can stop the use of rose bengal in other countries if indeed it works ,and how much profit Provectus can make if it is so cheap to produce , I understand the patents ,how long do they last in provectus case and would a big Pharma just wait till expiration then use the technology."
Will cancer patients wait 20+ years?
vorlon said...
"Big pharma going to wait 20 plus years?"
And I will be up huge again. In fact I will be up even more next time because I am now adding to my holdings. Buy when there is blood in the streets...
I'm not a trader and I don't "play" promos. My average basis is $1.76 and I'm in at least until we get those minutes from the FDA. At that time I will evaluate and make any necessary adjustments.
In the first 1:15 minutes this morning, 2.8 million shares of buying pushed the price to $6 per share. At lunch, selling 3.3 million shares in 30 minutes drove the price down to $2.74.
Those are the facts. Now we can only speculate as to why someone (or group of someones) decided to dump shares in a manner apparently designed to drive the price down.
The fact is that in situations where a stock is appreciating rapidly, buyers tend to set sell stops to protect their gains. Those sell stops are visible to all the major players. These "major players" can see where if they can start the dominos to falling, the price decline will feed on itself as more sell stops are triggered; thus leveraging your money for their nefarious purposes. Sometimes the decline can be triggered by a surprisingly small investment.
This strategy works best on small cap stocks like PVCT. Unfortunately, there are "wolves" out there. By setting sell stops, you are giving them the knowledge they need to separate you from your hard earned dollars.
You have to wonder if the powers that be are making a concerted effort to prevent PVCT from qualifying to up-list.
Well put.
Modrica said...
"ISCO is almost debt free entity (check financials) with lots of cash/funds into 2016
these are facts
next leg up should be coming real soon
once trials are underway we be looking at couple of bucks
in my opinion
gl
mod"
Excellent! Thanks for the info.
vorlon said...
"You did not go back far enough. A while back they tried to get on Nasdaq at $4 with preferred share offering. The common stock dropped and the conversion rate became too great to go through with it so they canceled the deal. But they paid the fees and did the paperwork then."
LOL! Bid 5.51 - Ask 5.50
New HOD - $5.50
I have seen some on here posting that the company has already done the paperwork to be up-listed. Can someone point to where that info came from? I do not see it in the company PRs. TIA
It looks like the MMs are pulling out all the stops to try and derail the train. When volume slows they put a big block of shares on the ask. Then they skip bids to give the impression of a major pullback to try to scare people into selling in the hopes that the additional selling will take the price down further. But then the price does not drop much before the buyers return. Apparently the buying volume is just too strong.
New HOD - $5.10
Did you download the free program and see what it had to say about PVCT?
Gulfbreeze said...
"Starting to be watched...
HOT STOCK"
http://www.hotstocked.com/article/74172/provectus-pharmaceuticals-inc-otcmkts-pvct.html
Of course this could be a case of buy the rumor, sell the news. But the upside is so huge, I'm not selling yet. Regardless of any pullbacks, I am convinced that this stock will be a big winner this year.
I was a buyer up to $2.82. So if it drops back to $2, I'll be buying more.
PVCTorBust said...
"what is worst case scenario to share price? we drop right back down to $2 or less?"
WOW! Will close at $5+?
The total dilution (~3.81 million new shares and ~2.48 million new warrants) is an increase of about 12.5% based on 50,000,000 current outstanding shares.
I was surprised by this because as part of the financing associated with the up-listing, we supposedly got enough money to cover "planned" expenses for 2 years. However, it appears from the PR that we have increased our planned expenses to advance some of the other drugs in our pipeline, thus the need for additional funding. If that is the case, (and I believe it is) then this will turn out to be good news.
Does anyone know what the fully-diluted share count is? (i.e. the total outstanding shares + outstanding warrants + convertible preferred shares [if any], etc.)
Thanks.
@Karin - BTW thanks for the note a few days ago!
@ DrKaz - You are correct. Bankruptcy is a ridiculous assertion given this company's current positive financial situation.
Don't forget the on-going Kevetrin phase 1 trial...
Sox said...
1. Brilacidin phase 2b for ABSSSI
2. Prurisol phase 2/3 for psoriasis
3. Brilacidin phase 1/2 for oral mucositis
4. Kevetrin combo trial for AML
5. Kevetrin combo trial for renal caner
Kevetrin phase 2 might start in 2014 as well, depends on when phase 1 is finished. Hope this helps, Mr. Bundy, Polk High football legend. =)
You are correct. ISCO's finances are in very good shape for an early stage biotech.
Are you sure that this is the right video?
Keep up the good work. It is appreciated.
Thanks.
Modrica said...
yes and ISCO will have even more cash to use for RnD from revenues it is generating
for the 3 months ended September , 30 , 2013 ISCO had 4,4 millions revenues and cost of revenues were 1,1 million
so as we can see ISCO was using 3,3 mill. cash from gross profits last 3 quarters 2013
so basically if revenues pattern continues this year ISCO will also have , on top of 5.45 mill from July financing and 10.25 millions $ December financing , around 4-5 millions $ to use from gross profits fro their needs
as we can see ISCO is way stronger fundamentally than immediate competitors (actc,gern,btx,etc..) that are valued 10,15 ,20 x more than ISCO
very soon market should come to ralization how undervalued isco is
so i said my guess is that with both financing and gross profits from revenues ISCO is secured cash-wise well into 2016
everybody should do their own DD and do their buys or sells based on factual current information and not outdated forward looking statements
in my opinion
gl
mod
Thank you modrica for this accurate information.
modrica said...
ISCO secured almost 16 millions $ since July , that will be enough till 2016 at least
people read from conference calls :
<< read the fact from cc :
<< in July we raised approximately $3 million, most of which came from a group of new investors new to ISCO. The capital will be used to fund our R&D programs, primarily our Parkinson's disease program where we intend to start a clinical trial in 2014.
As part of the offering, we also issued B Warrants which expired in October of this year, and we now have, through the execution of these B Warrants, raised a total of about $5.45 million from this transaction which along with our continued ability to manage our burn rate successfully downwards, now funds the Company well into 2014. >>
so funds raise in July will get ISCO well into 2014
In December ISCO secured another 10.25 millions $ from With Lincoln Park Capital Fund, LLC
10.25 millios will be with minimal dilution because there are no warrants or convertibles
The Company controls the timing and amount of any future investment and LPC is obligated to make such purchases.
read :
<< There are no upper limits to the price LPC may pay to purchase ISCO common stock .... and .... LPC has agreed not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of the Company's shares of common stock >>
ih.advfn.com/p.php?pid=nmona&article=60351106
these are all facts and not forward looking statements
on top 5 millions yearly revenues and increasing
revenues has increased for last 4 quarters and trend is expected to continue
ISCO in 2013 had more than 3 millions in gross profits
imo
gl
mod
Scottrade says $6.05
Mjzgrk said...
Why on my fidelity it says "last price" at 5.87$ and on yahoo stock ticker 6.31$?
This is a real opportunity for NNVC. The bar is much lower for animal meds. It might well be that all that is required for usage is that you prove to one of the big integrators (like Smithfield) that your medication will work and not affect the meat. For this PED Virus in the US alone the revenue could be $10 to $20 million per year. And from what we are told, they could develop a PEDcide in just a few weeks.
The question would be can NNVC produce commercial quantities of the medication? If not, a company like Smithfield would probably be willing to front the money for building a GMP quality plant in return for the sole rights to distribute NNVC's viral medications (like PEDV) for the pork industry.
That way NNVC gets a commercial quantity production facility and a dedicated customer for that product. We really need such a production facility. It would allow us to control the production of our product so as to make it more difficult for others to steal our technology and produce it in another country.
I would think that this could be pursued as a parallel track that would not impact the timeline for Flucide. Perhaps one of you who is in contact with the good docs at NNVC can float this idea for their consideration. I have contacts at Smithfield and would be glad to facilitate this engagement.
Thanks for the response! A follow up question if I may...
If not ASCO, when would you expect to see the results (i.e. tumor regression) for Cohorts 6 & 7? Will the company release such info in a PR?
Details of Cohort 6 were not ready for this conference. Apparently Cohort 5 had a least one person with tumor regression which leaves me (and everyone else) anticipating good news going forward. Do one of you CTIX long-timers here know the answers to the following questions?
1) Will the details (specifically noting additional patients with tumor regression) for Cohort 6 be released by the company before ASCO?
2) Do you think that those results for Cohort 7 will be available by ASCO?
TIA...
Good info, even if it is a little dated...
It sounds like PVCT provided some additional information to the FDA which may have resulted in that "30 day" response requirement being pushed out a bit. That last sentence is particularly interesting.
From the 8K...
"Reference is made to Item 7.01 of the Current Report on Form 8-K of Provectus Biopharmaceuticals, Inc. (formerly Provectus Pharmaceuticals, Inc.) (the “Company”) dated December 18, 2013 and filed with the Commission on December 18, 2013, which is incorporated herein by this reference, announcing that the Company held a Type C meeting with the FDA Division of Oncology Products 2 on December 16, 2013 to discuss the Company’s oncology drug, PV-10.
Subsequently, the Company took the opportunity to provide input into the documentation of meeting minute notes. It is the opinion of the Company that this may have delayed the process of receiving the final meeting minute notes. Therefore, the Company will communicate further guidance from the FDA once the meeting minute notes have been received, which is expected shortly.
It is also the Company's opinion that the delay has no bearing on the FDA's decision regarding the efficacy of PV-10 but is rather a matter of observing governmental processes. This delay also has no bearing on the Company's discussions and negotiations with parties outside the FDA's jurisdiction."
If it qualifies as a material event, then the company usually has 4 days to file an 8K with the SEC.
Normally a company has 4 business days to file an 8K regarding a material event.
I think it is perfectly acceptable to discuss TA as it applies to GALT. Thank you for the instructive commentary.
NEWS... It's all good but I bolded a couple of statements below that caught my eye. Apparently we will get safety and efficacy information on the 1st cohort in about 11 weeks.
Galectin Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1 Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis
NORCROSS, Ga., Jan. 13, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that patient enrollment in the first cohort of a Phase 1 trial of GR-MD-02 is now complete. The first-in-man study, which has successfully enrolled eight patients in the first cohort, is evaluating the safety, tolerability, and exploratory biomarkers for efficacy for single and multiple doses of GR-MD-02 when administered to patients with fatty liver disease (NASH) with advanced fibrosis. Intervention in NASH patients with advanced fibrosis, with the intent of reversing the fibrosis, is a potentially important therapeutic approach in this unmet medical need.
The Phase 1 multi-center, partially-blinded clinical trial will be conducted in a total of 24 patients who will receive four weekly doses of GR-MD-02. Each of the three cohorts consists of eight patients, six randomized to receive active drug and two randomized to receive placebo. The study is being conducted at six U.S. centers with extensive experience in clinical trials in liver disease. Two additional centers have been added to aid in the prompt enrollment of the next cohort.
"Completion of enrollment in the first cohort is an important step toward Galectin Therapeutics' objective of bringing a first-in-class treatment to the millions of Americans suffering from fatty liver disease with advanced fibrosis," said Dr. Peter G. Traber, President, Chief Executive Officer, and Chief Medical Officer of Galectin Therapeutics Inc. "To date, we have seen no serious adverse events in the trial. Following the 70 day study period and analysis of the data, we anticipate that initial safety and tolerability results, as well as biomarkers to evaluate for potential disease effect, from the first cohort will be available around the end of the first quarter of this year."
GR-MD-02 is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of fatty liver disease and fibrosis. Galectin proteins play a major role in diseases that involve scaring of organs such as cancer, and inflammatory and fibrotic disorders. The drug binds to galectin proteins and disrupts their function. Preclinical data has shown that GR-MD-02 has robust treatment effects in reversing fibrosis and cirrhosis.
The trial is titled "A Multi-Center, Partially Blinded, Maximum Tolerated Multiple Dose Escalation, Phase 1 Clinical Trial to Evaluate the Safety of GR-MD-02 in Subjects with Non-Alcoholic Steatohepatitis (NASH) with Advanced Hepatic Fibrosis." Trial design details can be found at http://clinicaltrials.gov/ct2/show/NCT01899859?term=gt-020&rank=1.
In March 2013, the U.S. Food and Drug Administration (FDA) granted GR-MD-02 Fast Track designation for non-alcoholic steatohepatitis (NASH) with hepatic fibrosis, commonly known as fatty liver disease with advanced fibrosis.
About Fatty Liver Disease with Advanced Fibrosis
Non-alcoholic steatohepatitis (NASH), also known as fatty liver disease, has become a common disease of the liver with the rise in obesity rates, estimated to affect nine to 15 million people, including children, in the U.S. Fatty liver disease is characterized by the presence of fat in the liver along with inflammation and damage in people who drink little or no alcohol. Over time, patients with fatty liver disease can develop fibrosis, or scarring of the liver, and it is estimated that as many as three million individuals will develop cirrhosis, a severe liver disease where liver transplantation is the only current treatment available. Approximately 6,300 liver transplants are done on an annual basis in the U.S. There are no drug therapies approved for the treatment of liver fibrosis. FDA and AASLD (American Association for the Study of Liver Disease) recently held a 2-day workshop with leading scientific experts in NASH and key FDA officials to discuss acceptable regulatory endpoints for approval of drugs to treat NASH (http://www.aasld.org/additionalmeetings/Pages/aasldfdanash.aspx).
About Galectin Therapeutics
Galectin Therapeutics (Nasdaq:GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.
Forward Looking Statements
This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as "may," "estimate, " "could," "expect" and others. They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. These statements include those regarding the anticipated timing of release of safety, tolerability and potential biomarker results among others. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others, completion of the clinical trial protocols by the enrolled patients and processing of the resulting data. Future clinical studies may not begin or produce positive results in a timely fashion, if at all, and could prove time consuming and costly. Plans regarding development, approval and marketing of any of our drugs are subject to change at any time based on the changing needs of our company as determined by management and regulatory agencies. Regardless of the results of current or future studies, we may be unsuccessful in developing partnerships with other companies or obtaining capital that would allow us to further develop and/or fund any studies or trials. To date, we have incurred operating losses since our inception, and our ability to successfully develop and market drugs may be impacted by our ability to manage costs and finance our continuing operations. For a discussion of additional factors impacting our business, see our Annual Report on Form 10-K for the year ended December 31, 2012, and our subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.
CONTACT: Galectin Therapeutics Inc.
Peter G. Traber, MD, 678-620-3186
President, CEO, & CMO
ir@galectintherapeutics.com
(MORE TO FOLLOW) Dow Jones Newswires
January 13, 2014 08:00 ET (13:00 GMT)
ICPT's new treatment for NASH apparently has a not so good side-effect. It increased bad cholesterol and lowered good cholesterol. (See below)
Maybe all this news (good and bad) for ICPT raised the profile for GALT. Maybe that increased attention to the huge market that is NASH/fibrosis/cirrhosis will result in some additional investors for GALT. Perhaps some of those ICPT investors will want to diversify into a company that is bringing forward a treatment that actually REVERSES fibrosis in multiple organs. We'll see...
"Patients who received Intercept Pharmaceuticals' (ICPT) beticholic acid (OCA) for the treatment of NASH in a trial for the chronic liver disease experienced increased bad cholesterol and lower good cholesterol, the NIH said after the close on Friday in a statement to the WSJ.
The NIH said it was releasing the information to give "broader context" to its earlier findings that OCA showed a "highly statistically significant improvement" in measures of liver health vs. those who received a placebo
Intercept didn't mention cholesterol abnormalities in two statements it put out on Thursday, nor in a subsequent analyst call. While the NIH told Intercept earlier in the week that patients had experienced "lipid effects," it failed to furnish Intercept with details. "We had no concrete data with respect to lipids," CEO Mark Pruzanski said.
Pruzanski told the WSJ that previous studies have shown that OCA can raise lipid levels, and it was already "very public" that OCA "impacts lipid metabolism."
Intercept's shares skyrocketed 516% on Thursday and Friday to $445.83 following news of the early ending of the study."
Did you mean to say NVAX or NNVC?
ZF said...
"One of my important criteria for choosing investments is that the probability of success (IMHO, of course) should be grossly underestimated by the market. And IMHO that is very much the case with NVAX."
Please post a link for the webcast. Thanks in advance.